JPBiomed will support and represent Acolyte in conducting training, product support and technical support with a growing number of distributors
Acolyte Biomedica, which recently introduced its new BacLiteflex Rapid MRSA system for screening of potentially colonised patients, has announced the creation of a trading partnership agreement with JPBiomed for customer support services in international markets.
JPBiomed specialises in providing bespoke technical and customer support services to the clinical diagnostics industry.
It will support and represent Acolyte in conducting training, product support and technical support with a growing number of distributors.
This role will include front line support for distributors.
Since its introduction to the European market in January, the BacLite flex Rapid MRSA system has achieved positive adoption by a growing number of private and public hospitals for routine screening.
It is the only available objective rapid screening test for MRSA which is culture-based and therefore able to differentiate between viable and dead cells.
This partnership is intended to allow rapid expansion of the installed base whilst providing the highest levels of field customer support.
Tim Coombs, Acolyte's chairman, commented "JPBiomed is the perfect partner to facilitate our growth in screening for Healthcare Associated Infections (HAIs)".
"It has already demonstrated its capabilities in support of BioStat, our exclusive distributor in Great Britain."
